Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 70
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Transpl Int ; 34(4): 606-608, 2021 04.
Article in English | MEDLINE | ID: mdl-33797146

ABSTRACT

To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch. The Transplant Trial Watch is a monthly overview of 10 new randomised controlled trials (RCTs) and systematic reviews. This page of Transplant International offers commentaries on methodological issues and clinical implications on 2 articles article of particular interest from the CET Transplant Trial Watch monthly selection. For all high quality evidence in solid organ transplantation, visit the Transplant Library: www.transplantlibrary.com.


Subject(s)
Organ Transplantation , Humans , Randomized Controlled Trials as Topic , Systematic Reviews as Topic
2.
Transpl Int ; 34(8): 1335-1337, 2021 08.
Article in English | MEDLINE | ID: mdl-34180561

ABSTRACT

To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT (https://esot.org/) and the Centre for Evidence in Transplantation have developed the Transplant Trial Watch (www.transplantevidence.com). The Transplant Trial Watch is a monthly overview of 10 new randomized controlled trials (RCTs) and systematic reviews. This page of Transplant International offers commentaries on methodological issues and clinical implications on two articles of particular interest from the CET Transplant Trial Watch monthly selection. For all high quality evidence in solid organ transplantation, visit the Transplant Library: www.transplantlibrary.com.


Subject(s)
Organ Transplantation , Humans
3.
Transpl Int ; 34(10): 1751-1753, 2021 10.
Article in English | MEDLINE | ID: mdl-34528333

ABSTRACT

To keep the transplantation community informed about recently published level 1 evidence in organ transplantation ESOT (https://esot.org/) and the Centre for Evidence in Transplantation (www.transplantevidence.com) have developed the Transplant Trial Watch. The Transplant Trial Watch is a monthly overview of 10 new randomized controlled trials (RCTs) and systematic reviews. This page of Transplant International offers commentaries on methodological issues and clinical implications on two articles of particular interest from the CET Transplant Trial Watch monthly selection. For all high quality evidence in solid organ transplantation, visit the Transplant Library: www.transplantlibrary.com.


Subject(s)
Organ Transplantation , Humans
4.
Transpl Int ; 34(6): 996-998, 2021 06.
Article in English | MEDLINE | ID: mdl-33949003

ABSTRACT

To keep the transplantation community informed about recently published level 1 evidence in organ transplantation, ESOT (https://esot.org/) and the Centre for Evidence in Transplantation (https://www.transplantevidence.com/) have developed the Transplant Trial Watch. The Transplant Trial Watch is a monthly overview of 10 new randomized controlled trials (RCTs) and systematic reviews. This page of Transplant International offers commentaries on methodological issues and clinical implications on two articles of particular interest from the CET Transplant Trial Watch monthly selection. For all high-quality evidence in solid organ transplantation, visit the Transplant Library (www.transplantlibrary.com).


Subject(s)
Organ Transplantation , Humans , Randomized Controlled Trials as Topic
5.
Transpl Int ; 34(8): 1374-1385, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34062020

ABSTRACT

There is limited evidence regarding the impact of allograft nephrectomy (AN) on the long-term outcome of subsequent kidney re-transplantation compared with no prior allograft nephrectomy. The aim of the present study was to conduct a systematic review and meta-analysis to estimate the accumulation of evidence over time. Primary outcomes were 5-year graft and patient survival. Cochrane library, Google scholar, PubMed, Medline and Embase were systematically searched. Meta-analysis was conducted using both fixed- and random-effects models. Study quality was assessed in duplicate using the Newcastle-Ottawa scale. Sixteen studies were included, with a total of 2256 patients. All included studies were retrospective and comparative. There was no significant difference in 5-year graft survival (GS) [Hazard Ratio (HR) = 1.11, 95% Confidence Intervals (CI): 0.89, 1.38, P = 0.37, I2  = 10%) or in 5-year patient survival (PS; HR = 0.70, 95% CI: 0.45, 1.10, P = 0.12, I2  = 0%]. Patients in the AN cohort were significantly younger than patients in the nonallograft nephrectomy (NAN) cohort by one year. Prior allograft nephrectomy was associated with a significantly higher risk of delayed graft function (DGF), acute rejection, primary nonfunction (PNF), per cent of panel reactive antibodies (% PRA) and allograft loss of the subsequent transplant. Although, DGF, % PRA, acute rejection and primary nonfunction rates were significantly higher in the AN cohort, allograft nephrectomy prior to re-transplantation had no significant association with five-year graft and patient survival.


Subject(s)
Kidney Transplantation , Allografts , Graft Rejection , Graft Survival , Humans , Nephrectomy , Retrospective Studies
8.
9.
Transpl Int ; 37: 12711, 2024.
Article in English | MEDLINE | ID: mdl-38389709
12.
Curr Opin Organ Transplant ; 24(4): 411-415, 2019 08.
Article in English | MEDLINE | ID: mdl-31145158

ABSTRACT

PURPOSE OF REVIEW: A key aspect of posttransplant management is to identify and treat graft injury before it becomes irreversible. The gold-standard for detection is histology, but biopsy is uncomfortable for the patient and carries a risk of complications. Detection of changes at a molecular level may preempt histological injury, and thereby identify injury earlier. RECENT FINDINGS: Indicators of immune system activation, such as candidate chemokines CXCL9 and CXCL10, and by-products of neutrophil activity, have been related to acute rejection and early allograft function. Transcriptomic studies of multiple-gene panels have identified candidate combinations that have proven very promising in risk-stratification and prediction of acute rejection, as well as diagnosis of both T-cell-mediated and antibody-mediated rejection. Serum and urine cell-free DNA is also a promising area of investigation, particularly in antibody-mediated rejection. SUMMARY: Noninvasive, rapid, and accurate tests for risk-prediction and diagnosis in renal transplant allografts are urgently required. The ideal candidate is one that can be measured in either urine or blood, is cheap, and is both sensitive and specific for the condition of interest. Numerous strategies have been proposed, with varying degrees of clinical and preclinical success. A few that meet the essential criteria have been evaluated; a few have made it as far as clinical testing.


Subject(s)
Allografts/physiopathology , Biomarkers/blood , Graft Rejection/blood , Kidney Transplantation/methods , Humans
13.
Transpl Int ; 36: 11045, 2023.
Article in English | MEDLINE | ID: mdl-36713116
14.
Transpl Int ; 36: 11202, 2023.
Article in English | MEDLINE | ID: mdl-37025500
17.
Transpl Int ; 36: 12256, 2023.
Article in English | MEDLINE | ID: mdl-38020748
18.
Biomed Microdevices ; 20(1): 2, 2017 Nov 21.
Article in English | MEDLINE | ID: mdl-29159519

ABSTRACT

Integration of microelectronics with microfluidics enables sophisticated lab-on-a-chip devices for sensing and actuation. In this paper, we investigate a novel method for in-situ microfluidics fabrication and packaging on wafer level. Two novel photo-patternable adhesive polymers were tested and compared, PA-S500H and DXL-009. The microfluidics fabrication method employs photo lithographical patterning of spin coated polymer films of PA or DXL and direct bonding of formed microfluidics to a top glass cover using die-to-wafer level bonding. These new adhesive materials remove the need for additional gluing layers. With this approach, we fabricated disposable microfluidic flow cytometers and evaluated the performance of those materials in the context of this application. DXL-009 exhibits lower autofluorescence compared to PA-S500H which improves detection sensitivity of fluorescently stained cells. Results obtained from the cytotoxicity test reveals that both materials are biocompatible. The functionality of these materials was demonstrated by detection of immunostained monocytes in microfluidic flow cytometers. The flexible, fully CMOS compatible fabrication process of these photo-patternable adhesive materials will simplify prototyping and mass manufacturing of sophisticated microfluidic devices with integrated microelectronics.


Subject(s)
Adhesives/chemistry , Flow Cytometry/instrumentation , Lab-On-A-Chip Devices , Animals , Fibroblasts , Flow Cytometry/methods , Humans , Materials Testing , Mice , Polymers/chemistry , Signal-To-Noise Ratio
19.
Transpl Int ; 35: 10365, 2022.
Article in English | MEDLINE | ID: mdl-35418804
20.
Transpl Int ; 35: 10513, 2022.
Article in English | MEDLINE | ID: mdl-35651877

Subject(s)
Transplants , Humans
SELECTION OF CITATIONS
SEARCH DETAIL